The tesa/ipa stack combines tesamorelin and ipamorelin to raise growth hormone. Learn how the blend works, typical protocols, side effects, and FDA status.
The tesa/ipa stack is a research combination of tesamorelin, a growth hormone–releasing hormone (GHRH) analog, and ipamorelin, a selective ghrelin receptor agonist. The goal is to trigger growth hormone release through two different receptors at the same time. Tesamorelin is FDA-approved only as Egrifta SV for HIV-associated lipodystrophy, and ipamorelin is not FDA-approved for human use at all.
What the Tesa/IPA Stack Is and How It Works
Tesamorelin is a synthetic form of growth hormone–releasing hormone that binds GHRH receptors in the pituitary. Ipamorelin is a pentapeptide that mimics ghrelin and binds the GHS-R1a receptor. Because the two act on separate receptors, a GHRH analog and a ghrelin mimetic are frequently combined.
Growth hormone is released in pulses, mostly during deep sleep and after intense exercise. GHRH analogs such as tesamorelin increase the amplitude of those pulses, while ghrelin mimetics such as ipamorelin increase pulse frequency and help suppress somatostatin, the hormone that puts the brakes on GH release.
- Tesamorelin binds GHRH receptors and raises both GH and IGF-1 in clinical studies.
- Ipamorelin stimulates GH release with minimal effect on cortisol, prolactin, or appetite compared with older ghrelin mimetics.
- Together they are usually described as additive rather than redundant, because they act on separate pathways.
A tesa ipa blend peptide product typically ships as two separate vials, since the two compounds have different stability profiles and dosing ranges. Some vendors sell pre-mixed vials, but many users draw each compound separately or combine them in one syringe immediately before injection.
The synergy claim is largely extrapolated from research on other GHRH-plus-GHRP combinations. No large randomized trial has tested tesamorelin and ipamorelin used together in humans.
Typical Tesa/IPA Blend Protocol
Dosing varies widely, and most numbers circulating online come from forum posts rather than clinical trials. The table below reflects the ranges people most often discuss, not a medical recommendation.
| Compound | Commonly discussed dose | Frequency | Typical timing |
|---|---|---|---|
| Tesamorelin | 1–2 mg | Once daily | Before bed, empty stomach |
| Ipamorelin | 100–300 mcg | 1–3 times daily | Pre-bed; sometimes pre-workout |
| Cycle length | 8–12 weeks (tesamorelin trials ran 26 weeks) | — | Often followed by a break |
Most versions of the tesa ipa blend protocol that circulate online follow three rules: inject on an empty stomach, wait 20–30 minutes before eating, and dose close to sleep so the pulse lines up with the body's natural overnight release. Alcohol, high-sugar meals, and heavy carbohydrate intake near injection time are usually discouraged because they blunt GH secretion.
Threads on tesa/ipa blend reddit frequently debate whether one nightly dose of both compounds is enough or whether ipamorelin should be split into two or three smaller doses. There is no consensus, and no head-to-head data settle the question.
Tesa/IPA Blend Benefits People Report
The strongest human evidence belongs to tesamorelin alone. In FDA-reviewed trials of people with HIV-associated lipodystrophy, tesamorelin reduced visceral abdominal fat and improved waist circumference over 26 weeks.
- Visceral fat and waistline: the best-supported effect, but only in the population that was studied.
- Lean mass and recovery: widely reported anecdotally with GHRH/GHRP stacks, not proven for this specific pair.
- Sleep quality and skin: common forum claims with little controlled evidence behind them.
- IGF-1 elevation: measurable and expected, and also the main reason for lab monitoring.
Anyone researching tesa ipa blend benefits should treat forum reports as anecdotal. Response to growth hormone secretagogues varies from person to person, and expectations built on bodybuilding posts rarely match what controlled studies show.
Side Effects and Safety Considerations
Growth hormone secretagogues are not risk-free, even when they are marketed as gentle.
- Injection site reactions, redness, and irritation.
- Joint pain, stiffness, carpal tunnel–type numbness, and fluid retention.
- Increased appetite and possible changes in blood sugar.
- Elevated IGF-1, which is a concern with long-term use.
- Headache, fatigue, and injection-site nodules, which were reported with tesamorelin in trials.
Tesamorelin's label notes risks that include injection site reactions, joint pain, and changes in blood sugar. Ipamorelin has no approved human safety database. Anyone with a history of cancer, pituitary disease, or diabetes should consult a licensed healthcare professional before considering either peptide.
CJC/Ipa vs Tesa/Ipa: What the Difference Is
The comparison people search most often is cjc/ipa vs tesa/ipa. Both pair ipamorelin with a GHRH analog, but the GHRH component is different.
| Feature | CJC-1295/Ipamorelin | Tesamorelin/Ipamorelin |
|---|---|---|
| GHRH component | CJC-1295 | Tesamorelin |
| Half-life | ~30 minutes (no DAC) to ~7 days (with DAC) | ~26–38 minutes |
| FDA status | Not approved for human use | Tesamorelin approved for HIV lipodystrophy |
| Human trial data | Limited | Substantial, in one population |
| Typical dose | 100 mcg CJC-1295 + 100–300 mcg ipamorelin | 1–2 mg tesamorelin + 100–300 mcg ipamorelin |
CJC-1295 with DAC stays active far longer, which produces a sustained bleed of growth hormone instead of a clean pulse. Tesamorelin clears quickly, so it behaves more like natural GHRH. Stacking a long-acting and a short-acting GHRH analog together is sometimes discussed, and most experienced users say it makes timing harder rather than better.
Legal Status and Sourcing Reality
Tesamorelin requires a prescription in the United States when sold as Egrifta SV. Ipamorelin is sold as a research chemical and is labeled "not for human consumption." Buying either compound outside a pharmacy means no guarantee of purity, accurate dosing, or sterility.
Discussions on peptide forums often focus on vendor testing, third-party certificates of analysis, and cold-chain shipping. Those details matter, but they do not make an unapproved product safe or legal to use.
In short, the tesa/ipa stack rests on a plausible physiological rationale that has never been confirmed in a controlled human trial. Tesamorelin has real clinical data for visceral fat in HIV-associated lipodystrophy, and ipamorelin has very limited human data. Speaking with a licensed healthcare professional is the responsible first step for anyone considering these peptides.
RELATED PEPTIDE TOPICIpamorelin peptideFrequently Asked Questions
Is the tesa/ipa stack FDA-approved?
No. Tesamorelin is FDA-approved only as Egrifta SV for HIV-associated lipodystrophy, and ipamorelin is not approved for human use in the United States. The combination of the two has never been reviewed or approved by the FDA.
How much tesamorelin and ipamorelin do people stack?
Ranges discussed online usually run 1–2 mg of tesamorelin once daily alongside 100–300 mcg of ipamorelin one to three times daily, often timed before bed on an empty stomach. These numbers come from forum reports rather than clinical trials and are not a medical recommendation.
What is the difference between CJC/ipa and tesa/ipa?
Both stacks pair ipamorelin with a GHRH analog, but the GHRH component differs. CJC-1295 can stay active for days when it includes DAC, while tesamorelin clears in roughly half an hour and is the only one of the two with FDA approval and substantial human trial data.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.